[1]万鑫,王书楠,国巍,等.18F-FDG PET/CT对98例惰性B细胞淋巴瘤预后评估[J].第三军医大学学报,2019,41(04):366-370.
 WAN Xin,WANG Shunan,GUO Wei,et al.Prognostic value of 18F-FDG PET-CT for indolent B-cell lymphoma: analysis of 98 cases[J].J Third Mil Med Univ,2019,41(04):366-370.
点击复制

18F-FDG PET/CT对98例惰性B细胞淋巴瘤预后评估(/HTML )
分享到:

《第三军医大学学报》[ISSN:1000-5404/CN:51-1095/R]

卷:
41卷
期数:
2019年第04期
页码:
366-370
栏目:
临床医学
出版日期:
2019-02-28

文章信息/Info

Title:
Prognostic value of 18F-FDG PET-CT for indolent B-cell lymphoma: analysis of 98 cases
作者:
万鑫王书楠国巍唐杨王兴彤刘明锁白鸥
吉林大学第一医院肿瘤中心血液科
Author(s):
WAN Xin WANG Shunan GUO Wei TANG Yang WANG Xingtong LIU Mingsuo BAI Ou

Department of Hematology, Cancer Center, First Hospital of Jilin University, Changchun, Jilin Province, 130021, China

关键词:
惰性淋巴瘤B细胞PET/CTSUVmax
Keywords:
indolent lymphoma B cells positron emission tomography/computed tomography SUVmax
分类号:
R730.7; R733.4; R814.42
文献标志码:
A
摘要:

目的探讨治疗前18F-FDG PET/CT最大标准摄取值(maximum standardized uptake value, SUVmax)等临床因素对惰性B细胞淋巴瘤(indolent B-cell nontlodgkin’s lymphoma, B-iNHL)的预后判断价值。方法 收集2012-2017年本院收治的初诊且治疗前行PET/CT检查的98例B-iNHL患者的临床资料,分析治疗前SUVmax等临床因素与预后之间的关系。结果 98例B-iNHL患者中位SUVmax 6.8(1.8~25.4),其中滤泡性淋巴瘤(follicular lymphoma, FL)43例,中位SUVmax 7.8(3.6~20.3),非FL55例,中位SUVmax 5.3(1.8~25.4),差异有统计学意义(P=0.001)。依据SUVmax分为高SUVmax组(SUVmax>7.25)39例(39.8%);低SUVmax组(SUVmax≤7.25)59例(60.2%)。单因素及多因素分析显示SUVmax>7.25是影响无进展生存(progression-free survival, PFS)及总生存(overall survival, OS)的独立预后危险因素(P<0.05)。高SUVmax组3年PFS率为43.8%,显著低于SUVmax组(85.9%, P=0.001;高SUVmax组)3年OS率为79.0%,显著低于低SUVmax组(98.3%,P=0.002)。高SUVmax组病死率23.1%(9/39),低SUVmax组病死率1.7%(1/59),差异有统计学意义(P=0.001)。结论 18 F-FDG PET/CT SUVmax是影响B-iNHL患者PFS及OS的独立预后危险因素,对B-iNHL 患者预后判断具有一定参考价值。
 

Abstract:

Objective To investigate the value of the maximun standardized uptake value (SUVmax) in 18F-FDG PET-CT before treatment in predicting the survival outcomes of patients with indolent B-cell lymphoma (B-iNHL). Methods The clinical data were collected from 98 patients with B-iNHL diagnosed and treated in our hospital from January, 2012 to December, 2017. All the patients, including 43 with follicular lymphoma and 55 with nonfollicular lymphoma, underwent 18F-FDG PET-CT before treatment, and the correlation of SUVmax with the survival outcomes of the patients were analyzed. Results The median SUVmax was 6.8 (range 1.8-25.4) in the overall 98 patients with B-iNHL. The median SUVmax was significantly higher in patients with follicular lymphoma than those with nonfollicular lymphoma [7.8 (3.6-20.3) vs 5.3 (1.8-25.4)], P=0.001). According to the level of SUVmax, the 98 patients were divided into high SUVmax (>7.25; n=39) group and low SUVmax (≤7.25; n=59) group, and univariate and multivariate analyses showed that a SUVmax>7.25 was an independent risk factor that affected progression-free survival (PFS) and overall survival (OS) of the patients (P<0.05). Compared with those with low SUVmax before treatment, the patients with high SUVmax had a significantly lower 3-year estimated PFS rate (43.8% vs 85.9%, P<0.05) and 3-year estimated OS rate (79.0% vs 98.3%, P<0.05). Nine patients in high SUVmax group and 1 in low SUVmax group died, showing a significant difference in the mortality rate between the two groups (9/39 vs 1/59, 23.1% vs 1.7%, P=0.001). Conclusion SUVmax in 18F-FDG PET-CT is an independent risk factor affecting PFS and OS of the patients with B-iNHL and can be used as a predictor of the survival outcomes of the patients.

参考文献/References:

[1]MONTGOMERY N D, MATHEWS S P. Transformation in low-grade B-cell neoplasms[J]. Surg Pathol Clin, 2016, 9(1): 79-92. DOI: 10.1016/j.path.2015.09.004.

[2]WIRTH A. Indolentlymphomasoccurring in bone[J]. LeukLymphoma, 2014, 55(8): 1701-1702. DOI: 10.3109/10428194.2013.876635.

[3]METSER U, DUDEBOUT J, BAETZ T, et al. 18F-FDG PET/CT in the staging and management of indolent lymphoma: A prospective multicenter PET registry study: PET/CT in indolent lymphoma[J].Cancer, 2017, 123(15): 2860-2866. DOI: 10.1002/cncr.30672.

[4]CHO S F , CHANG C C , LIU Y C , et al. Utilization of 18F-FDG PET/CT as a staging tool in patients with newly diagnosed lymphoma[J]. Kaohsiung J Med Sci, 2015, 31(3): 130-137. DOI: 10.1016/j.kjms.2014.11.012.

[5]薛久巍, 于生龙, 马德爽, 等. 惰性B细胞淋巴瘤的临床特点与生存状况研究[J]. 中国医药科学, 2017, 7(5): 158-160. DOI: 10.3969/j.issn.2095-0616.2017.05.046.

XUE J W, YU S L, MA D S, et al. Clinical characteristics and survival status of patients with indolent B-cell nonHodgkin lymphoma[J].China Med Pharmacy, 2017, 7(5): 158-160. DOI: 10.3969/j.issn.2095-0616.2017.05.046.

[6]HASHMI A A, HUSSAIN Z F, FARIDI N, et al. Distribution of Ki67 proliferative indices among WHO subtypes of non-Hodgkin’s lymphoma: association with other clinical parameters[J]. Asia Pac J Cancer Prev, 2014, 15(20): 8759-8763. DOI: 10.7314/APJCP.2014.15.20.8759.

[7]张建华, 王荣福, 范岩, 等. 18F-FDG PET/CT评价初诊非霍奇金淋巴瘤代谢活性及其与免疫表型的相关性[J]. 中华医学杂志, 2014, 94(33): 2576-2579. DOI: 10.3760/cma.j.issn.0376-2491.2014.33.006.

ZHANG J H, WANG R F, FAN Y, et al. Metabolic activity measured by 18F-FDG PET/CT in newly diagnosed patients with non-Hodgkin lymphoma: correlation with immunophenotype[J]. Natl Med J China, 2014, 94(33): 2576-2579. DOI: 10.3760/cma.j.issn.0376-2491.2014.33.006.

[8]刘艳, 沈丽达, 杨小芸, 等. PET/CT 应用于恶性淋巴瘤诊治中的临床价值[J]. 现代医药卫生, 2016, 32(19): 2982-2986. DOI: 10.3969/j.issn.1009-5519.2016.19.016.

LIU Y, SHEN L D , YANG X Y, et al. Clinical value of PET/CT applied in diagnosis and treatment of malignant lymphoma[J].J Mod Med Health, 2016, 32(19): 2982-2986. DOI: 10.3969/j.issn.1009-5519.2016.19.016.

[9]ALOBTHANI G, ROMANOV V, ISOHASHI K, et al. Value of 18F-FDG PET/CT in discrimination between indolent and aggressive non-Hodgkin’s lymphoma: A study of 328 patients[J]. Hell J Nucl Med, 2018, 21(1): 7-14. DOI: 10.1967/s002449910701.

[10]NGEOW J Y, QUEK R H, NG D C, et al. High SUV uptake on FDG-PET/CT predicts for an aggressive B-cell lymphoma in a prospective study of primary FDGPET/CT staging in lymphoma[J]. Ann Oncol, 2009, 20(9): 1543-1547. DOI: 10.1093/annonc/mdp030.

[11]程志祥, 魏征, 邹善华, 等. 不同病理类型非霍奇金淋巴瘤18F-氟代脱氧葡萄糖PET/CT标准摄取值的比较[J]. 中国临床医学, 2015, 22(5): 586-588.

CHENG Z X, WEI Z, ZOU S H, et al. Comparison of the standarized uptake value of fluorine-18Flurodeoxyglucose PET/CT among different type of non-hodgkin lymphoma[J]. Chin J Clin Med, 2015, 22(5): 586-588.

[12]戴云秀, 杨光杰, 王振光, 等. 18FFDG PET/CT基线SUVmax在滤泡性淋巴瘤侵袭性、分期评价中的价值及其与中期疗效的相关性研究[J]. 国际放射医学核医学杂志, 2018, 42(2): 104-110.

DAI Y X,YANG G J,WANG Z G, et al.Evaluation of invasiveness staging and correlation with interim therapeutic response based on baseline 18F-FDG PET/CT SUVmax in patients with follicular lymphoma[J]. Int J Radiat Med Nucl Med, 2018, 42(2): 104-110.

[13]TYCHYJPINEL C, RICARD F, FULHAM M, et al. PET/CT assessment in follicular lymphoma using standardized criteria: central review in the PRIMA study[J]. Eur J Nucl Med Mol Imaging, 2014, 41(3): 408-415.DOI:  10.1007/s00259-013-2441-8.

[14]丁重阳, 孙晋, 李天女, 等. 治疗前18FFDG PET/CT最大标准摄取值在滤泡性淋巴瘤的预后价值[J]. 中国实验血液学杂志, 2015, 23(5): 1331-1335. DOI: 10.7534/j.issn.1009-2137.2015.05.020.

DING C Y, SUN J, LI T N, et al. Prognostic value of maximum standard uptake on pretreatment 18F-FDG PET/CT scan in newly diagnosed follicular lymphoma[J]. J Exp Hematol, 2015, 23(5): 1331-1335. DOI: 10.7534 /j.issn.1009-2137.2015.05.020.

[15]SUZUKI R. Indolent B-cell lymphoma: the current standard in 2014[J]. J Clin Exp Hematop, 2014, 54(1): 1-2. DOI: 10.3960/jslrt.54.1.

 

相似文献/References:

[1]冯起甲,徐智,吴国明,等.脂多糖结合蛋白的B细胞抗原表位预测及其效应初步分析[J].第三军医大学学报,2008,30(04):292.
 FENG Qi-jia,XU Zhi WU Guo-ming,HU Chuan-min,et al.Prediction of B-cell antigen epitope on lipopolysaccharidebinding protein[J].J Third Mil Med Univ,2008,30(04):292.
[2]杨清浩,王祥卫,金燕,等.MUC1抗原的B细胞表位预测[J].第三军医大学学报,2005,27(05):406.
[3]李红,苏敏,杨宇,等.人胎阑尾淋巴组织及T、B淋巴细胞的发育[J].第三军医大学学报,2010,32(16):1766.
 Li Hong,Su Min,Yang Yu,et al.Histogenesis of lymphoid tissue and development of T and B lymphocytes in human fetal appendix[J].J Third Mil Med Univ,2010,32(04):1766.
[4]陈泽林,王祥卫,康俊.原发性睾丸非霍奇金淋巴瘤1例[J].第三军医大学学报,2010,32(05):453.

更新日期/Last Update: 2019-02-22